Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vivus endocrine/metabolic news

Vivus investor First Manhattan Co. said Anthony Zook agreed to serve as the biotech's CEO if First Manhattan's slate of proposed directors are elected to the Vivus board at the company's upcoming July 15 annual general meeting. Zook was president of the MedImmune LLC biologics unit of

Read the full 475 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers